gemfibrozil has been researched along with fenofibrate in 146 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (4.11) | 18.7374 |
| 1990's | 36 (24.66) | 18.2507 |
| 2000's | 62 (42.47) | 29.6817 |
| 2010's | 40 (27.40) | 24.3611 |
| 2020's | 2 (1.37) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
| Chae, YN; Chang, DJ; Jung, JW; Kang, HJ; Kim, MK; Kim, NJ; Koo, BW; Le, TV; Lee, KO; Li, F; Lim, JI; Moon, SH; Paek, SM; Park, HJ; Ryu, JS; Shin, CY; Shin, DH; Suh, YG | 1 |
| Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF | 1 |
| Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bhatia, G; Khanna, AK; Kumar, M; Sashidhara, KV; Singh, BS; Sonkar, R | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bhatia, G; Pandeti, S; Shukla, A; Sonkar, R; Tadigoppula, N | 1 |
| Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Huff, MW | 1 |
| Alvarez, L; Aránega, A; Aránega, AE; Fernández, JE; González, FJ; Muros, MA; Prados, J; Vélez, C | 1 |
| Alvarez, L; Aránega, A; Aránega, AE; Fernández, JE; González, FJ; Linares, A; Muros, MA; Vélez, C | 1 |
| Schwandt, P | 1 |
| Frishman, WH; Kahn, S; Zimetbaum, P | 1 |
| Kłosiewicz-Latoszek, L; Szostak, WB | 1 |
| Arsenio, L; Rossi, A | 1 |
| Krause, BR; Newton, RS | 1 |
| Clavey, V; Fruchart, JC; Marzin, D; Olivier, P; Plancke, MO; Sauzieres, J | 1 |
| Hunninghake, DB; Peters, JR | 1 |
| Grundy, SM; Vega, GL | 1 |
| Santafé Oroz, J; Segarra Domènech, J | 1 |
| Alvarez, L; Aránega, A; Aránega, AE; Gonzalez, AR; Melguizo, C; Muros, MA; Vélez, C | 1 |
| Schonfeld, G | 1 |
| Dujovne, CA; Lozada, A | 1 |
| Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Auwerx, J; Grimaldi, P; Schoonjans, K; Staels, B | 1 |
| Shepherd, J | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| Walsh, KB; Wang, C | 1 |
| Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME | 1 |
| Aranega, A; Aranega, AE; Gonzalez, FJ; Melguizo, C; Prados, JC; Velez, MC | 1 |
| Diemer, S; Eberlein-König, B; Przybilla, B | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Grover, S; Hamilton, VH; Lavoie, F; Perreault, S | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Chen, JW; Jen, SL; Lee, WL; Wang, SP | 1 |
| Canudas, N; Rivas, C; Sarabia, Z; Torrealba, A; Vargas, F | 1 |
| Miller, DB; Spence, JD | 1 |
| Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP | 1 |
| Sinzinger, H | 1 |
| Bays, HE; Dujovne, CA | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Bergemann, R; Brandt, A; Siegrist, W | 1 |
| Wallace, KB; Zhou, S | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Bellamy, FD; Chaput, E; Edgar, AD; Maubrou-Sanchez, D | 1 |
| Baugé, E; Chinetti, G; Clavey, V; Copin, C; Dallongeville, J; Fruchart, J; Fruchart, JC; Mariotte, MC; Staels, B | 1 |
| Gylys, KH | 1 |
| Bruno, A; Cassader, M; Fornengo, P; Gambino, R; Pagano, G | 1 |
| Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C | 1 |
| Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB | 1 |
| Bargman, JM; Cattran, D; Lewis, GF; Lipscombe, J | 1 |
| Elisaf, M; Kakafika, A; Tsimihodimos, V | 1 |
| Dierkes, J; Luley, C; Westphal, S | 1 |
| Hombach, V; Marx, N | 1 |
| Bostom, AG | 1 |
| Chan, NN; Chow, FC | 1 |
| Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V | 1 |
| Keating, GM; Ormrod, D | 1 |
| Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C | 1 |
| Bullano, MF; Corbelli, JC; Corbelli, ME; Cziraky, MJ; Waugh, W; Willey, VJ | 1 |
| Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL | 1 |
| Bellido, A; Cabrero, A; Laguna, JC; Novell, F; Rodríguez, C; Roglans, N; Ros, E; Zambón, D | 1 |
| Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB | 1 |
| Davidson, MH | 2 |
| Dejager, S; Farnier, M; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Maki, KC | 1 |
| Alegret, M; Laguna, JC; Novell, F; Roglans, N; Ros, E; Sánchez, RM; Vázquez-Carrera, M; Zambón, D | 1 |
| Cousins, M; Edwards, AL; Nakajima, K; Ooi, DS; Ooi, TC | 1 |
| Chavis, JA; Choy, J; Diab, A; Drew, PD; Hussain, RZ; Lovett-Racke, AE; Matthes, L; Northrop, S; Racke, MK; Rocchini, A | 1 |
| Baldwin, GS; Ford, J; Lachal, S; Shulkes, A | 1 |
| Bellosta, S; Corsini, A; Paoletti, R | 1 |
| Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J | 1 |
| Alsheikh-Ali, AA; Karas, RH; Kuvin, JT | 1 |
| Duez, H; Dzavik, V; Fiévet, C; Fruchart, JC; Gineste, R; Gonzalez, FJ; Helleboid, S; Lefebvre, B; Lefebvre, P; Luc, G; Percevault, F; Peters, JM; Poulain, P; Staels, B; Torra, IP | 1 |
| Davidson, MH; Jones, PH | 1 |
| Hay, JW; Sterling, KL | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Duriez, P; Fruchart, JC | 1 |
| Bloomfield, HE | 1 |
| Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR | 1 |
| Andrade, SE; Blough, D; Burgess, M; Chan, KA; Graham, D; La Grenade, L; Platt, R; Schech, S; Shatin, D; Staffa, J; Stergachis, A | 1 |
| Isidori, M; Nardelli, A; Parrella, A; Pascarella, L; Rubino, M | 1 |
| Bauman, JN; Davis, JA; Goosen, TC; Hurst, SI; Loi, CM; Williams, JA; Yu, C | 1 |
| Berneis, K; Rizzo, M | 1 |
| Bouhlel, MA; Chinetti-Gbaguidi, G; Staels, B | 1 |
| Alsheikh-Ali, AA; Holoshitz, N; Karas, RH | 1 |
| Chrysohoou, C; Singh, S | 1 |
| Gonzalez, FJ; Hossain, MA; Tsujita, M; Yokoyama, S | 1 |
| Brinton, EA | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Kołodziejczyk, MK; Lukosek, M; Nachajski, MJ; Woskowicz, MH; Zgoda, MM | 1 |
| Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG | 1 |
| Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
| Ben, LH; Drew, PD; Gocke, AR; Hussain, RZ; Lovett-Racke, AE; Peng, H; Racke, MK; Stuve, O; Weiner, J; Yang, Y | 1 |
| Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G | 1 |
| Bode, C; Ernst, S; Leugers, A; Nordt, TK; Sobel, BE; Willecke, F; Zirlik, A | 1 |
| Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL | 1 |
| Dunn, FL | 1 |
| Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR | 1 |
| Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Mancusi, C; Metelli, MR; Orlando, C; Pupilli, C | 1 |
| Guo, Q; Liu, X; Namura, S; Wang, G | 1 |
| Blanco-Vaca, F; Calpe-Berdiel, L; Escolà-Gil, JC; Hernández, C; Jauhiainen, M; Julve, J; Llaverías, G; Rotllan, N; Simó, R | 1 |
| Bloomgarden, ZT; Drexler, A | 1 |
| Amend, KL; Landon, J; McAfee, A; Niemcryk, S; Thyagarajan, V | 1 |
| Almad, A; Lash, AT; Lovett-Racke, AE; McTigue, DM; Wei, P | 1 |
| Huang, KH; Lee, CY; Lin, CC; Shih, HC; Tsai, TH | 1 |
| Corbett, GT; Ghosh, A; Gonzalez, FJ; Pahan, K | 1 |
| Brown, E; Crane, HM; Delaney, JA; Eron, JJ; Hunt, PW; Kahn, JO; Kitahata, MM; Liu, W; Mathews, WC; Mugavero, MJ; Muñoz, MA; Napravnik, S; Saag, MS; Willig, JH | 1 |
| Biswas-Legrand, S; Chandrachud, U; Coppel, SH; Cotman, SL; Crystal, RG; Goss, KA; Gusella, JF; Haggarty, SJ; Haliw, L; Hermann, A; Lojewski, X; Lucente, D; Petcherski, A; Reinhardt, P; Schöler, H; Selig, MK; Sheridan, SD; Simas, AM; Sims, KB; Sondhi, D; Staropoli, JF; Sterneckert, J; Storch, A | 1 |
| Oliveira, HC; Patrício, PR; Raposo, HF; Simões, MC | 1 |
| Jacob, RF; Mason, RP | 1 |
| Ann, SJ; Chung, JH; Jang, J; Kang, SM; Kim, SH; Lee, SH; Park, BH; Park, S | 1 |
| Fernández, K; Israel, Y; Karahanian, E; Muñoz, D; Quintanilla, ME; Rivera-Meza, M | 1 |
| Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D | 1 |
| Heo, TH; Hong, M; Jun, HS; Kim, SJ; Lee, HK; Lee, YS; Song, KD; Yi, S | 1 |
| Béliard-Lasserre, S | 1 |
| Bu, S; Chu, Z; Gonzale, FJ; Han, L; Li, P; Liu, A; Min, L; Song, D; yang, J; Zhen, T | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Bu, S; Dai, M; Gonzalez, FJ; Liu, A; Luo, M; Song, D; Wang, W; Zhang, B | 1 |
| Hiromori, Y; Hu, J; Ido, A; Meng, L; Nagase, H; Nakanishi, T; Usuda, H; Yang, M | 1 |
| Chen, J; Li, C; Lu, Y; Peijnenburg, WJGM; Qu, J; Xie, Q; Zhang, YN; Zhao, J; Zhou, Y | 1 |
| Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T | 1 |
| Gottschalk, CG; Jana, M; Kundu, M; Pahan, K; Roy, A | 1 |
| Fruchart, JC; Santos, RD | 1 |
| Can, LH; İbrahimov, F; Kayıkçıoğlu, M; Shahbazova, S | 1 |
| Hong, YH; Ma, MS; Qiu, ZQ; Sun, ZX; Wei, M; Xu, YW; Yuan, YH; Zhang, ZJ | 1 |
33 review(s) available for gemfibrozil and fenofibrate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides | 1991 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids | 1987 |
Fibric acids: effects on lipids and lipoprotein metabolism.
Topics: Bezafibrate; Bile Acids and Salts; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Pentanoic Acids; Triglycerides | 1987 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids | 1994 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL | 1993 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides | 1996 |
[Mechanism of phototoxicity induced by drugs].
Topics: 4-Quinolones; Anti-Infective Agents; Butyrates; Dermatitis, Phototoxic; Drug-Related Side Effects and Adverse Reactions; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Photochemistry; Photolysis | 1996 |
Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Topics: Anticholesteremic Agents; Clofibrate; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver; Mixed Function Oxygenases; Warfarin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Drug interactions of lipid-altering drugs.
Topics: Contraindications; Drug Interactions; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol; Resins, Plant | 1998 |
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Nursing Research; Patient Compliance | 2000 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Ligands; Male; Mice; Muscle, Smooth, Vascular; Peroxisome Proliferators; Rats; Research; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Databases, Bibliographic; Diabetes Mellitus, Type 2; Drug Delivery Systems; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Combination lipid-lowering therapy in diabetes.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Safety | 2003 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Metabolic Syndrome; Prevalence | 2004 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced Liver Injury; Citrus; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Polymorphism, Genetic; Polymyositis; Rhabdomyolysis | 2004 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment | 2004 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Risk Factors | 2006 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome | 2007 |
Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Macrophages; Peroxisome Proliferator-Activated Receptors | 2008 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2006 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Triglycerides | 2008 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Gemfibrozil; Humans; PPAR alpha | 2019 |
12 trial(s) available for gemfibrozil and fenofibrate
| Article | Year |
|---|---|
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Topics: Adult; Aged; Cross-Over Studies; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Single-Blind Method | 1997 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Adult; Aged; Creatinine; Cross-Over Studies; Cystatin C; Cystatins; Fenofibrate; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Lipids; Male; Middle Aged | 2001 |
Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
Topics: Acyl-CoA Oxidase; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Carnitine O-Palmitoyltransferase; Cholecystectomy; Cholelithiasis; Cholesterol, HDL; Cholesterol, LDL; DNA Primers; Female; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Male; Middle Aged; Oxidoreductases; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Stearoyl-CoA Desaturase; Transcription Factors; Triglycerides | 2002 |
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino Acid Substitution; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Models, Molecular; Pancreatic Elastase; Protein Binding; Protein Conformation; Secondary Prevention; Structure-Activity Relationship | 2003 |
Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.
Topics: Bezafibrate; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Down-Regulation; Female; Fenofibrate; Gallstones; Gemfibrozil; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Topics: Adolescent; Adult; Aged; Animals; Apolipoprotein A-I; Cholesterol, HDL; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Mice; Mice, Transgenic; Middle Aged; PPAR alpha; RNA, Messenger; Species Specificity; Triglycerides | 2005 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones | 2006 |
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; PPAR alpha | 2008 |
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Topics: Adult; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Fenofibrate; Gemfibrozil; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lactones; Male; Middle Aged; Pyrroles | 2011 |
102 other study(ies) available for gemfibrozil and fenofibrate
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Topics: Animals; Cell Line; Drug Design; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Phenylpropionates; PPAR alpha; PPAR gamma; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation | 2008 |
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides | 2009 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
Topics: Animals; Anti-Obesity Agents; Bile Acids and Salts; Butyrates; Dietary Fats; Fatty Liver; Feces; Feeding Behavior; Fibric Acids; Hyperlipidemias; Hypolipidemic Agents; Indoles; Intra-Abdominal Fat; Lipoproteins, LDL; Liver; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Propionates; Rats; Structure-Activity Relationship; Weight Loss | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
Topics: Animals; Antioxidants; Disease Models, Animal; Diterpenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Molecular Structure; Oxidation-Reduction; Rats; Rats, Inbred Strains | 2013 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Fibrates and HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins | 1991 |
Effects of fibric acid derivatives on accumulation of actin in myocardiocytes.
Topics: Actins; Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Immunoblotting; Myocardium | 1991 |
Influence of fibric acid derivatives on intermediate filament proteins in myocardiocyte cultures.
Topics: Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeletal Proteins; Desmin; Fenofibrate; Gemfibrozil; Heart; In Vitro Techniques; Intermediate Filament Proteins; Myocardium; Vimentin | 1991 |
Fibrates and triglyceride metabolism.
Topics: Bezafibrate; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol | 1991 |
[Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives].
Topics: Adult; Bezafibrate; Drug Evaluation; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Propionates; Time Factors | 1989 |
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates | 1986 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofibrate; Gemfibrozil; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Mice; Mice, Inbred Strains; Niacin; Pentanoic Acids; Triglycerides | 1988 |
Changes in subcellular accumulation of contractile proteins in myocardiocyte cultures: effects of fibric acid derivatives.
Topics: Actinin; Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Contractile Proteins; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Immunoblotting; Myocardial Contraction; Myocardium; Tropomyosin; Troponin; Troponin T | 1993 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation.
Topics: Adipose Tissue; Animals; Clofibrate; Coenzyme A Ligases; Diet; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Glucocorticoids; Heart; Kidney; Liver; Liver Neoplasms, Experimental; Male; Mice; Microbodies; Myocardium; Oxidation-Reduction; Rats; Rats, Wistar; Repressor Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured | 1993 |
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S | 1996 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Effect of chloride channel blockers on the cardiac CFTR chloride and L-type calcium currents.
Topics: Animals; Anthracenes; Calcium; Calcium Channel Blockers; Chloride Channels; Chlorides; Clofibric Acid; Colforsin; Cystic Fibrosis Transmembrane Conductance Regulator; Fenofibrate; Gemfibrozil; Glycolates; Guinea Pigs; Ion Transport; Mice; Myocardium; ortho-Aminobenzoates; Patch-Clamp Techniques; Stilbenes | 1996 |
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Topics: Animals; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides | 1995 |
Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives.
Topics: Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeleton; Densitometry; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Intermediate Filament Proteins; Myocardium | 1995 |
Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region.
Topics: Bezafibrate; Clofibrate; Dermatitis, Phototoxic; Drug Evaluation, Preclinical; Fenofibrate; Gemfibrozil; Hemolysis; Humans; Hypolipidemic Agents; In Vitro Techniques; Ultraviolet Rays | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1998 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome | 1993 |
The effect of peroxisome proliferators on mitochondrial bioenergetics.
Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.
Topics: Animals; Bezafibrate; Drug Synergism; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley; Vitamin E | 1999 |
Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Blood; Carcinoma, Hepatocellular; Cattle; Culture Media; DNA-Binding Proteins; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Liver Neoplasms; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII.
Topics: Adult; Apolipoprotein C-II; Apolipoproteins C; Combined Modality Therapy; Drug Resistance; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Treatment Failure | 2000 |
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea | 2000 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin | 2000 |
Deterioration in renal function associated with fibrate therapy.
Topics: Adult; Aged; Creatinine; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Retrospective Studies | 2001 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Triglycerides | 2001 |
Fibrate treatment can increase serum creatinine levels.
Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Urea | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Creatinine; Fenofibrate; Gemfibrozil; Glomerular Filtration Rate; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Reproducibility of Results | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Fenofibrate; Fibrinogen; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2001 |
Effects of various fibrates on serum alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome | 2002 |
Effects of fibrates on metabolism of statins in human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Safety; Transaminases; Treatment Outcome | 2002 |
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
Topics: Aged; Chi-Square Distribution; Coronary Disease; Cross-Over Studies; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Retrospective Studies | 2002 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged | 2003 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Retrospective Studies; Sex Factors; Treatment Outcome; Triglycerides | 2003 |
Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia.
Topics: Cholesterol; Dietary Fats; Diterpenes; Fasting; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Postprandial Period; Retinyl Esters; Triglycerides; Vitamin A | 2004 |
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.
Topics: Animals; Cell Line; Cell Line, Transformed; Cell Survival; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Fenofibrate; Gemfibrozil; Growth Inhibitors; Humans; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbodies; Microglia; Nitric Oxide; Receptors, Cytoplasmic and Nuclear; T-Lymphocyte Subsets; Th2 Cells; Transcription Factors | 2004 |
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2004 |
Risk of adverse events with fibrates.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver Diseases; Male; Middle Aged; Rhabdomyolysis; Risk Factors; Treatment Failure; United States | 2004 |
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Topics: Adverse Drug Reaction Reporting Systems; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Retrospective Studies; Rhabdomyolysis; United States; United States Food and Drug Administration | 2005 |
Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Topics: Aged; Cholesterol, HDL; Coronary Disease; Cost-Benefit Analysis; Female; Fenofibrate; Gemfibrozil; Health Care Costs; Humans; Male; Middle Aged; Risk Reduction Behavior | 2005 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
The role of fibrates in a statin world.
Topics: Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Peroxisome Proliferator-Activated Receptors | 2006 |
Risk factors for statin-associated rhabdomyolysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Drug Therapy, Combination; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Diseases; Male; Middle Aged; Odds Ratio; Rhabdomyolysis; Risk Factors; Sex Factors | 2007 |
Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms.
Topics: Aliivibrio fischeri; Animals; Bezafibrate; Chlorophyta; Crustacea; Escherichia coli; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Lethal Dose 50; Mutagenicity Tests; No-Observed-Adverse-Effect Level; Rotifera; Salmonella typhimurium; Toxicity Tests, Acute; Toxicity Tests, Chronic; Ultraviolet Rays; Water Pollutants, Chemical | 2007 |
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Catalysis; Drug Interactions; Fenofibrate; Gemfibrozil; Glucuronic Acid; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lactones; Microsomes, Liver; Models, Biological; Molecular Structure; Pyrroles; Recombinant Proteins; Tandem Mass Spectrometry; Uridine Diphosphate Glucuronic Acid | 2007 |
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Prescriptions; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Liver Diseases; Muscular Diseases; Rhabdomyolysis; United States; United States Food and Drug Administration | 2008 |
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles | 2008 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Solubilizing properties of new surface-active agents, products of selective oxyethylation of cholic acid. Part I.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chlorates; Diclofenac; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Ketoprofen; Micelles; Models, Theoretical; Nifedipine; Solubility; Solutions; Surface-Active Agents; Vasodilator Agents; Viscosity | 2007 |
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease.
Topics: Animals; Blotting, Western; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Fenofibrate; GATA3 Transcription Factor; Gemfibrozil; Gene Expression Regulation; Immunologic Factors; Interleukin-4; Interleukin-5; Mice; Mice, Transgenic; PPAR alpha; Promoter Regions, Genetic; T-Box Domain Proteins; Transcription, Genetic; Transfection | 2009 |
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Nutrition Surveys; Prevalence; United States; Young Adult | 2009 |
Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Animals; Cells, Cultured; Female; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Humans; Hypolipidemic Agents; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Plasminogen Activator Inhibitor 1; PPAR alpha; Stem Cells; Transforming Growth Factor beta | 2009 |
CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
Topics: Adult; Chemokine CXCL11; Chemokine CXCL9; Cytokines; Female; Fenofibrate; Gemfibrozil; Graves Disease; Humans; Interferon-gamma; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; T-Lymphocytes; Thiazolidinediones; Thyroid Gland; Thyroidectomy | 2010 |
Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels.
Topics: Animals; Brain; Brain Ischemia; Fenofibrate; Gemfibrozil; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microvessels; Neuroprotective Agents; Oxidative Stress; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxide Dismutase | 2010 |
Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo.
Topics: Animals; Apolipoprotein A-I; Biological Transport; Cell Line; Cholesterol; Feces; Female; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipid Metabolism; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Random Allocation; RNA, Messenger | 2011 |
Fibrate use in diabetes: new concepts.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents | 2011 |
Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Topics: Cohort Studies; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Electronic Health Records; Female; Fenofibrate; Follow-Up Studies; Gemfibrozil; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Insurance, Health; Male; Pharmacoepidemiology; Retrospective Studies; Rhabdomyolysis; Risk; United States | 2011 |
The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.
Topics: Animals; Dose-Response Relationship, Drug; Female; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Macrophages; Mice; Mice, Inbred C57BL; Motor Activity; Myelitis; Nerve Fibers, Myelinated; PPAR alpha; Recovery of Function; Spinal Cord; Spinal Cord Injuries; T-Lymphocytes; Treatment Failure | 2011 |
A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Taiwan | 2012 |
Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.
Topics: Aminopeptidases; Animals; Astrocytes; Brain; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Developmental; Humans; Hypolipidemic Agents; Lysosomes; Mice; Neuronal Ceroid-Lipofuscinoses; Neurons; PPAR alpha; Retinoid X Receptor alpha; Serine Proteases; Tripeptidyl-Peptidase 1; Up-Regulation | 2012 |
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Effectiveness Research; Drug Interactions; Female; Fenofibrate; Fish Oils; Gemfibrozil; Heptanoic Acids; HIV Infections; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; North Carolina; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; San Francisco; Treatment Outcome; Triglycerides; Washington | 2013 |
Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway.
Topics: Aminopeptidases; Blotting, Western; Case-Control Studies; Cell Proliferation; Cells, Cultured; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Electrophysiology; Endoplasmic Reticulum; Fenofibrate; Fibroblasts; Gemfibrozil; Golgi Apparatus; Humans; Immunoenzyme Techniques; Induced Pluripotent Stem Cells; Lysosomes; Membrane Glycoproteins; Models, Neurological; Molecular Chaperones; Mutation; Neuronal Ceroid-Lipofuscinoses; Neurons; Serine Proteases; Tripeptidyl-Peptidase 1 | 2014 |
Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
Topics: Animals; Bezafibrate; Cholesterol Ester Transfer Proteins; Combined Modality Therapy; Corn Oil; Crosses, Genetic; Dietary Supplements; Female; Fenofibrate; Fibric Acids; Fish Oils; Gemfibrozil; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Male; Mice, Transgenic; Random Allocation; RNA, Messenger; Up-Regulation | 2014 |
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles | 2015 |
PPARα agonists inhibit inflammatory activation of macrophages through upregulation of β-defensin 1.
Topics: Animals; Anti-Inflammatory Agents; beta-Defensins; Cell Line; Culture Media, Conditioned; Dose-Response Relationship, Drug; Fenofibrate; Gemfibrozil; Inflammation; Inflammation Mediators; Lipopolysaccharides; Macrophage Activation; Macrophages; Mice; Oxazoles; PPAR alpha; RNA Interference; Signal Transduction; Toll-Like Receptor 4; Transfection; Tyrosine; Up-Regulation | 2015 |
PPARα Agonists Reduce Alcohol Drinking: Do They Act in the Brain or in the Liver?
Topics: Alcohol Drinking; Animals; Brain; Fenofibrate; Gemfibrozil; Humans; Liver; Mice; PPAR alpha; PPAR gamma; Rats | 2015 |
Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential.
Topics: Apoptosis; Autophagy; Bezafibrate; Cells, Cultured; Fenofibrate; Gemfibrozil; Humans; Lymphocytes; Membrane Glycoproteins; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Neuronal Ceroid-Lipofuscinoses; Neuroprotective Agents; Oxidative Stress; PPAR alpha | 2016 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; France; Gemfibrozil; Guidelines as Topic; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pancreatitis; Randomized Controlled Trials as Topic; Risk Factors | 2015 |
Gemfibrozil not fenofibrate decreases systemic glucose level via PPARα.
Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Fenofibrate; Gemfibrozil; Glucose; Glycogen; Hepatomegaly; Hypolipidemic Agents; Liver; Mice; Mice, 129 Strain; Mice, Knockout; PPAR alpha; Pyruvate Kinase | 2016 |
PPARα-dependent increase of mouse urine output by gemfibrozil and fenofibrate.
Topics: Alanine Transaminase; Aldosterone; Animals; Arginine Vasopressin; Aspartate Aminotransferases; Blood Urea Nitrogen; Creatinine; Diuretics; Fenofibrate; Gemfibrozil; Hepatomegaly; Homeostasis; Kidney; Liver; Male; Mice; Mice, Knockout; PPAR alpha | 2017 |
Occurrence of fibrates and their metabolites in source and drinking water in Shanghai and Zhejiang, China.
Topics: China; Chromatography, Liquid; Drinking Water; Environmental Monitoring; Fenofibrate; Gemfibrozil; Humans; Solid Phase Extraction; Tandem Mass Spectrometry; Water Pollutants, Chemical; Water Purification | 2017 |
Unveiling the important roles of coexisting contaminants on photochemical transformations of pharmaceuticals: Fibrate drugs as a case study.
Topics: China; Fenofibrate; Gemfibrozil; Hydrogen-Ion Concentration; Light; Models, Theoretical; Molecular Structure; Pharmaceutical Preparations; Photolysis; Rivers; Water Pollutants, Chemical | 2018 |
PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Fenofibrate; Fibric Acids; Gemfibrozil; Glucose Intolerance; Hypolipidemic Agents; Metabolic Syndrome; Mice; Mice, Knockout; PPAR alpha; STAT3 Transcription Factor; Triglycerides | 2018 |
Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.
Topics: Administration, Oral; Animals; Base Sequence; Dopaminergic Neurons; Female; Fenofibrate; Gemfibrozil; Mice, Inbred C57BL; Neurons; Nuclear Receptor Subfamily 4, Group A, Member 2; PPAR alpha; Promoter Regions, Genetic; Substantia Nigra; Up-Regulation | 2019 |
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Diabetes Mellitus; Female; Fenofibrate; Fibric Acids; Follow-Up Studies; Gemfibrozil; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Obesity; Predictive Value of Tests; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Triglycerides; Young Adult | 2020 |
Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Fenofibrate; Gemfibrozil; Glucose-6-Phosphatase; Glycogen Storage Disease Type I; Humans; Hyperlipidemias; Hypolipidemic Agents; Infant; Infant, Newborn; Lipid Metabolism; Male; Mutation; Retrospective Studies; Starch; Triglycerides; Young Adult | 2020 |